<p>Cowa LLC 在第二季度收购了 Eli Lilly and Company（纽约证券交易所代码：LLY - 免费报告）的新股份，根据该公司最近向证券交易委员会提交的 13F 表格。该公司收购了 282 股，价值约为 220,000 美元。</p>
<ul>
<li>一项宏伟的人工智能投资？Stanley Druckenmiller 的最新科技动态</li>
</ul>
<p>其他几家对冲基金最近也买卖了 LLY 的股票。Braun Bostich &amp; Associates Inc.在第二季度将其在 Eli Lilly and Company 的持股增加了 2.5%。Braun Bostich &amp; Associates Inc.现在拥有 527 股该公司的股票，价值 411,000 美元，此前在上个季度又购买了 13 股。Rise Advisors LLC 在第二季度将其在 Eli Lilly and Company 的持股增加了 1.8%。Rise Advisors LLC 现在拥有 732 股该公司的股票，价值 571,000 美元，此前在上个季度又收购了 13 股。Occidental Asset Management LLC 在第二季度将其在 Eli Lilly and Company 的股份增加了 0.7%。Occidental Asset Management LLC 现在拥有 1,966 股该公司的股票，价值 1,533,000 美元，此前在上个季度又购买了 13 股。New Insight Wealth Advisors 在第二季度将其在 Eli Lilly and Company 的股份增加了 3.4%。New Insight Wealth Advisors 现在拥有 394 股该公司的股票，价值 307,000 美元，此前在上个季度又购买了 13 股。最后，Dash Acquisitions Inc.在第二季度将其在 Eli Lilly and Company 的持股增加了 2.8%。Dash Acquisitions Inc.现在拥有 485 股该公司的股票，价值 387,000 美元，此前在上个季度又购买了 13 股。82.53% 的股票由机构投资者和对冲基金持有。</p>
<p>获取 <strong>Eli Lilly and Company</strong> 的提醒：</p>
<h2>分析师升级和降级</h2>
<p>一些股票研究分析师最近对 LLY 股票发布了报告。汇丰银行在 10 月 1 日的报告中将 Eli Lilly and Company 的目标价格从 700.00 美元上调至 800.00 美元。Cantor Fitzgerald 在 10 月 31 日的研究报告中将 Eli Lilly and Company 的目标价格从 925.00 美元上调至 985.00 美元，并给予该股票 “超配” 评级。瑞银集团在 11 月 7 日的研究报告中将 Eli Lilly and Company 的目标价格从 895.00 美元上调至 1,080.00 美元，并给予该公司 “买入” 评级。Berenberg Bank 在 9 月 17 日的研究报告中重申了 “持有” 评级，并将 Eli Lilly and Company 的目标价格设定为 830.00 美元（之前为 970.00 美元）。最后，斯科舍银行在 11 月 13 日的报告中开始覆盖 Eli Lilly and Company。他们对该股票设定了 “行业表现优于大盘” 的评级和 1,165.00 美元的目标价格。三位分析师给予该股票 “强烈买入” 评级，十五位分析师给予 “买入” 评级，七位分析师给予 “持有” 评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，共识目标价格为 1,027.95 美元。</p>
<ul>
<li>HIMS 经历了过山车般的旅程。投资者应该加入吗？</li>
</ul>
<p><strong>获取我们关于 Eli Lilly and Company 的最新股票报告</strong></p>
<h2>Eli Lilly and Company 股票表现</h2>
<p>纽约证券交易所 LLY 的股票在周五开盘价为 1,058.05 美元。Eli Lilly and Company 的 12 个月低点为 623.78 美元，12 个月高点为 1,066.65 美元。该公司的市值为 1.00 万亿美元，市盈率为 69.15，市盈率/增长比率为 1.21，贝塔值为 0.43。该公司的 50 日移动平均线为 855.89 美元，200 日移动平均线为 787.66 美元。该公司的速动比率为 1.00，流动比率为 1.28，债务与股本比率为 1.86。</p>
<ul>
<li>年初至今下跌 45%，Novo Nordisk 引发价格战</li>
</ul>
<p>Eli Lilly and Company（纽约证券交易所代码：LLY - 获取免费报告）最近在 10 月 30 日宣布了其季度财报。该公司报告每股收益（EPS）为 7.02 美元，超过了共识预期的 6.42 美元，超出 0.60 美元。Eli Lilly and Company 的净利润率为 25.91%，股本回报率为 92.72%。该公司在本季度的收入为 176 亿美元，而共识预期为 160.9 亿美元。去年同期，该公司每股收益为 1.18 美元。Eli Lilly and Company 的季度收入同比增长 53.9%。Eli Lilly and Company 已将其 2025 财年的指导目标设定为 23.000-23.700 EPS。分析师平均预计 Eli Lilly and Company 在当前年度将发布 23.48 EPS。</p>
<h2>Eli Lilly and Company 宣布分红</h2>
<p>该公司最近还披露了一项季度分红，将于 12 月 10 日（星期三）支付。11 月 14 日（星期五）的股东将获得每股 1.50 美元的分红。除息日为 11 月 14 日（星期五）。这代表着每年 6.00 美元的分红和 0.6% 的分红收益率。Eli Lilly and Company 的派息比率目前为 29.35%。</p>
<h2>关于 Eli Lilly and Company</h2>
<p>（免费报告）</p>
<p>Eli Lilly and Company 在全球范围内发现、开发和销售人用药物。该公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素 lispro、胰岛素 lispro 原料、胰岛素 lispro 混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用于糖尿病；Jardiance、Mounjaro 和 Trulicity 用于 2 型糖尿病；Zepbound 用于肥胖。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更喜欢的五只股票超过 Eli Lilly and Company</li>
<li>复利是如何计算的？</li>
<li>一项宏伟的人工智能投资？Stanley Druckenmiller 的最新科技动态</li>
<li>如何使用 MarketBeat 分红计算器</li>
<li>12 位分析师刚刚提高了 CrowdStrike 的目标——他们预见了什么</li>
<li>零售投资者如何交易多伦多证券交易所（TSX）？</li>
<li>Palo Alto Networks 的股票刚刚回调——这是一个理想的买入区吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
<p>在考虑礼来公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前立即购买的股票……而礼来公司并不在名单上。</p>
<p>尽管礼来公司目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

礼来

<p>Cowa LLC 收购了 282 股礼来，价值 220,000 美元。分析师们发布了各种评级，普遍目标价为 1,027.95 美元。礼来的股票开盘价为 1,058.05 美元，12 个月最高价为 1,066.65 美元。该公司报告的季度每股收益为 7.02 美元，超出预期，收入为 176 亿美元，同比增长 53.9%</p>

<p>Cowa LLC acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The firm acquired 282 shares of the company's stock, valued at approximately $220,000.</p>
<div class="lb-trans"><p>Cowa LLC 在第二季度收购了 Eli Lilly and Company（纽约证券交易所代码：LLY - 免费报告）的新股份，根据该公司最近向证券交易委员会提交的 13F 表格。该公司收购了 282 股，价值约为 220,000 美元。</p>
</div><ul>
<li>A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves</li>
</ul>
<div class="lb-trans"><ul>
<li>一项宏伟的人工智能投资？Stanley Druckenmiller 的最新科技动态</li>
</ul>
</div><p>Several other hedge funds also recently bought and sold shares of LLY. Braun Bostich &amp; Associates Inc. increased its holdings in Eli Lilly and Company by 2.5% in the second quarter. Braun Bostich &amp; Associates Inc. now owns 527 shares of the company's stock worth $411,000 after buying an additional 13 shares during the last quarter. Rise Advisors LLC grew its position in Eli Lilly and Company by 1.8% in the second quarter. Rise Advisors LLC now owns 732 shares of the company's stock worth $571,000 after acquiring an additional 13 shares in the last quarter. Occidental Asset Management LLC increased its stake in shares of Eli Lilly and Company by 0.7% during the 2nd quarter. Occidental Asset Management LLC now owns 1,966 shares of the company's stock worth $1,533,000 after purchasing an additional 13 shares during the last quarter. New Insight Wealth Advisors increased its stake in shares of Eli Lilly and Company by 3.4% during the 2nd quarter. New Insight Wealth Advisors now owns 394 shares of the company's stock worth $307,000 after purchasing an additional 13 shares during the last quarter. Finally, Dash Acquisitions Inc. raised its holdings in shares of Eli Lilly and Company by 2.8% during the 2nd quarter. Dash Acquisitions Inc. now owns 485 shares of the company's stock valued at $387,000 after purchasing an additional 13 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他几家对冲基金最近也买卖了 LLY 的股票。Braun Bostich &amp; Associates Inc.在第二季度将其在 Eli Lilly and Company 的持股增加了 2.5%。Braun Bostich &amp; Associates Inc.现在拥有 527 股该公司的股票，价值 411,000 美元，此前在上个季度又购买了 13 股。Rise Advisors LLC 在第二季度将其在 Eli Lilly and Company 的持股增加了 1.8%。Rise Advisors LLC 现在拥有 732 股该公司的股票，价值 571,000 美元，此前在上个季度又收购了 13 股。Occidental Asset Management LLC 在第二季度将其在 Eli Lilly and Company 的股份增加了 0.7%。Occidental Asset Management LLC 现在拥有 1,966 股该公司的股票，价值 1,533,000 美元，此前在上个季度又购买了 13 股。New Insight Wealth Advisors 在第二季度将其在 Eli Lilly and Company 的股份增加了 3.4%。New Insight Wealth Advisors 现在拥有 394 股该公司的股票，价值 307,000 美元，此前在上个季度又购买了 13 股。最后，Dash Acquisitions Inc.在第二季度将其在 Eli Lilly and Company 的持股增加了 2.8%。Dash Acquisitions Inc.现在拥有 485 股该公司的股票，价值 387,000 美元，此前在上个季度又购买了 13 股。82.53% 的股票由机构投资者和对冲基金持有。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Eli Lilly and Company</strong> 的提醒：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级和降级</h2>
</div><p>A number of equities research analysts recently issued reports on LLY shares. HSBC upped their price objective on shares of Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. Cantor Fitzgerald upped their price target on Eli Lilly and Company from $925.00 to $985.00 and gave the stock an &#34;overweight&#34; rating in a research note on Friday, October 31st. UBS Group raised their price objective on Eli Lilly and Company from $895.00 to $1,080.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, November 7th. Berenberg Bank reaffirmed a &#34;hold&#34; rating and set a $830.00 target price (down previously from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Finally, Scotiabank assumed coverage on Eli Lilly and Company in a report on Thursday, November 13th. They set a &#34;sector outperform&#34; rating and a $1,165.00 price target on the stock. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and seven have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $1,027.95.</p>
<div class="lb-trans"><p>一些股票研究分析师最近对 LLY 股票发布了报告。汇丰银行在 10 月 1 日的报告中将 Eli Lilly and Company 的目标价格从 700.00 美元上调至 800.00 美元。Cantor Fitzgerald 在 10 月 31 日的研究报告中将 Eli Lilly and Company 的目标价格从 925.00 美元上调至 985.00 美元，并给予该股票 “超配” 评级。瑞银集团在 11 月 7 日的研究报告中将 Eli Lilly and Company 的目标价格从 895.00 美元上调至 1,080.00 美元，并给予该公司 “买入” 评级。Berenberg Bank 在 9 月 17 日的研究报告中重申了 “持有” 评级，并将 Eli Lilly and Company 的目标价格设定为 830.00 美元（之前为 970.00 美元）。最后，斯科舍银行在 11 月 13 日的报告中开始覆盖 Eli Lilly and Company。他们对该股票设定了 “行业表现优于大盘” 的评级和 1,165.00 美元的目标价格。三位分析师给予该股票 “强烈买入” 评级，十五位分析师给予 “买入” 评级，七位分析师给予 “持有” 评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，共识目标价格为 1,027.95 美元。</p>
</div><ul>
<li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li>
</ul>
<div class="lb-trans"><ul>
<li>HIMS 经历了过山车般的旅程。投资者应该加入吗？</li>
</ul>
</div><p><strong>Get Our Latest Stock Report on Eli Lilly and Company</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Eli Lilly and Company 的最新股票报告</strong></p>
</div><h2>Eli Lilly and Company Stock Performance</h2>
<div class="lb-trans"><h2>Eli Lilly and Company 股票表现</h2>
</div><p>Shares of NYSE LLY opened at $1,058.05 on Friday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,066.65. The company has a market cap of $1.00 trillion, a P/E ratio of 69.15, a P/E/G ratio of 1.21 and a beta of 0.43. The business's 50 day moving average is $855.89 and its two-hundred day moving average is $787.66. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.</p>
<div class="lb-trans"><p>纽约证券交易所 LLY 的股票在周五开盘价为 1,058.05 美元。Eli Lilly and Company 的 12 个月低点为 623.78 美元，12 个月高点为 1,066.65 美元。该公司的市值为 1.00 万亿美元，市盈率为 69.15，市盈率/增长比率为 1.21，贝塔值为 0.43。该公司的 50 日移动平均线为 855.89 美元，200 日移动平均线为 787.66 美元。该公司的速动比率为 1.00，流动比率为 1.28，债务与股本比率为 1.86。</p>
</div><ul>
<li>Down 45% Year-to-Date, Novo Nordisk Ignites a Price War</li>
</ul>
<div class="lb-trans"><ul>
<li>年初至今下跌 45%，Novo Nordisk 引发价格战</li>
</ul>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter last year, the company posted $1.18 earnings per share. Eli Lilly and Company's quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.</p>
<div class="lb-trans"><p>Eli Lilly and Company（纽约证券交易所代码：LLY - 获取免费报告）最近在 10 月 30 日宣布了其季度财报。该公司报告每股收益（EPS）为 7.02 美元，超过了共识预期的 6.42 美元，超出 0.60 美元。Eli Lilly and Company 的净利润率为 25.91%，股本回报率为 92.72%。该公司在本季度的收入为 176 亿美元，而共识预期为 160.9 亿美元。去年同期，该公司每股收益为 1.18 美元。Eli Lilly and Company 的季度收入同比增长 53.9%。Eli Lilly and Company 已将其 2025 财年的指导目标设定为 23.000-23.700 EPS。分析师平均预计 Eli Lilly and Company 在当前年度将发布 23.48 EPS。</p>
</div><h2>Eli Lilly and Company Announces Dividend</h2>
<div class="lb-trans"><h2>Eli Lilly and Company 宣布分红</h2>
</div><p>The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company's payout ratio is presently 29.35%.</p>
<div class="lb-trans"><p>该公司最近还披露了一项季度分红，将于 12 月 10 日（星期三）支付。11 月 14 日（星期五）的股东将获得每股 1.50 美元的分红。除息日为 11 月 14 日（星期五）。这代表着每年 6.00 美元的分红和 0.6% 的分红收益率。Eli Lilly and Company 的派息比率目前为 29.35%。</p>
</div><h2>About Eli Lilly and Company</h2>
<div class="lb-trans"><h2>关于 Eli Lilly and Company</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>Eli Lilly and Company 在全球范围内发现、开发和销售人用药物。该公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素 lispro、胰岛素 lispro 原料、胰岛素 lispro 混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用于糖尿病；Jardiance、Mounjaro 和 Trulicity 用于 2 型糖尿病；Zepbound 用于肥胖。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>How is Compound Interest Calculated?</li>
<li>A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves</li>
<li>How to Use the MarketBeat Dividend Calculator</li>
<li>12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming</li>
<li>How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?</li>
<li>Palo Alto Networks Stock Just Pulled Back—Is This a Prime Buy Zone?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票超过 Eli Lilly and Company</li>
<li>复利是如何计算的？</li>
<li>一项宏伟的人工智能投资？Stanley Druckenmiller 的最新科技动态</li>
<li>如何使用 MarketBeat 分红计算器</li>
<li>12 位分析师刚刚提高了 CrowdStrike 的目标——他们预见了什么</li>
<li>零售投资者如何交易多伦多证券交易所（TSX）？</li>
<li>Palo Alto Networks 的股票刚刚回调——这是一个理想的买入区吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在礼来公司吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑礼来公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前立即购买的股票……而礼来公司并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管礼来公司目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Cowa LLC 购买了 282 股 Eli Lilly 公司的股票$LLY